NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 9 hours 27 min ago

Maintaining Integrity in NIH Peer Review: Responsibilities and Consequences

Fri, 12/22/2017 - 11:00
Notice NOT-OD-18-115 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Partnership for Aging and Cancer Research (U01 - Clinical Trial Not Allowed)

Fri, 12/22/2017 - 10:59
Funding Opportunity PAR-18-552 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite U01 grant applications focused on advancing the understanding of mechanisms mediating aging in cancer. Qualifying applications must propose aging in cancer studies that are collaborations between non-NIH Principal Investigators (PIs) and intramural PIs from NCI and/or NIA as a co-investigator.
Categories: NIH-Funding

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed)

Thu, 12/21/2017 - 13:47
Funding Opportunity RFA-DA-18-023 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement [FOA] is to support research that will define and validate a set(s) of molecular biomarkers and/or bio-signatures indicating the degree of loss of functional reserve, or of resilience of the host defense mechanisms, at different phases of HIV-1 pathogenesis in individuals with substance use disorders (SUDs).
Categories: NIH-Funding

Notice of Correction to Eligibility Information in PAR-17-190 "Maximizing Investigators' Research Award for Early Stage Investigators (R35)"

Thu, 12/21/2017 - 13:34
Notice NOT-GM-18-013 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32 - Clinical Trial Not Allowed)

Thu, 12/21/2017 - 13:28
Funding Opportunity PAR-18-524 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing therapy development for Alzheimer's disease (AD) and AD-related dementias. This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e. basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational and clinical research for AD and AD-related dementias.
Categories: NIH-Funding

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01 - Clinical Trial Optional)

Thu, 12/21/2017 - 13:09
Funding Opportunity PA-18-545 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch. Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation. This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs). The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities. Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the relevant parent R01 FOA.
Categories: NIH-Funding

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)

Thu, 12/21/2017 - 12:41
Funding Opportunity PAR-18-530 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that it is will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users.. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation
Categories: NIH-Funding

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)

Thu, 12/21/2017 - 12:38
Funding Opportunity RFA-DK-17-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for type 1 diabetes (T1D) treatment.
Categories: NIH-Funding

Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44- Clinical Trial Not Allowed)

Thu, 12/21/2017 - 12:20
Funding Opportunity RFA-DK-17-029 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.
Categories: NIH-Funding

NeuroNEXT Clinical Trials (U01 - Clinical Trial Optional)

Thu, 12/21/2017 - 11:46
Funding Opportunity PAR-18-528 from the NIH Guide for Grants and Contracts. This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Categories: NIH-Funding

BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required)

Thu, 12/21/2017 - 11:33
Funding Opportunity RFA-NS-18-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without need for significant additional non-clinical data. For more information on the BRAIN PPP, see http://braininitiative.nih.gov/BRAIN_PPP/.
Categories: NIH-Funding

BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required)

Thu, 12/21/2017 - 11:33
Funding Opportunity RFA-NS-18-022 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.
Categories: NIH-Funding

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 - Clinical Trial Required)

Thu, 12/21/2017 - 11:33
Funding Opportunity RFA-NS-18-023 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without need for significant additional non-clinical data. For more information on the BRAIN PPP, see http://braininitiative.nih.gov/BRAIN_PPP/.
Categories: NIH-Funding

Notice of Correction to Key Dates for PAR-18-022 "Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)"

Thu, 12/21/2017 - 11:31
Notice NOT-CA-18-030 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01 - Clinical Trial Not Allowed)

Thu, 12/21/2017 - 11:13
Funding Opportunity RFA-AG-18-022 from the NIH Guide for Grants and Contracts. This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the ApoE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/crosstalk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.
Categories: NIH-Funding

Notice of Changes in PAR-16-149 "Archiving and Documenting Child Health and Human Development Data Sets (R03)"

Thu, 12/21/2017 - 11:01
Notice NOT-HD-17-028 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional)

Thu, 12/21/2017 - 11:00
Funding Opportunity PAR-18-533 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.
Categories: NIH-Funding

Notice of NIDDK's Participation in PAR-18-190 "Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)"

Thu, 12/21/2017 - 10:19
Notice NOT-DK-18-006 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding